HomeCompareCBLI vs VICI

CBLI vs VICI: Dividend Comparison 2026

CBLI yields 63.09% · VICI yields 6.52%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VICI wins by $208.9K in total portfolio value· pulled ahead in Year 10
10 years
CBLI
CBLI
● Live price
63.09%
Share price
$3.17
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$757.3K
Annual income
$183,899.77
Full CBLI calculator →
VICI
VICI Properties Inc.
● Live price
6.52%
Share price
$27.32
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$966.2K
Annual income
$607,376.13
Full VICI calculator →

Portfolio growth — CBLI vs VICI

📍 VICI pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCBLIVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CBLI + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CBLI pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CBLI
Annual income on $10K today (after 15% tax)
$5,362.78/yr
After 10yr DRIP, annual income (after tax)
$156,314.80/yr
VICI
Annual income on $10K today (after 15% tax)
$554.58/yr
After 10yr DRIP, annual income (after tax)
$516,269.71/yr
At 15% tax rate, VICI beats the other by $359,954.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CBLI + VICI for your $10,000?

CBLI: 50%VICI: 50%
100% VICI50/50100% CBLI
Portfolio after 10yr
$861.8K
Annual income
$395,637.94/yr
Blended yield
45.91%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

CBLI
Analyst Ratings
3
Buy
1
Hold
Consensus: Buy
Altman Z
435.1
Piotroski
1/9
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+15.7% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CBLI buys
0
VICI buys
0
No recent congressional trades found for CBLI or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCBLIVICI
Forward yield63.09%6.52%
Annual dividend / share$2.00$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3%
Portfolio after 10y$757.3K$966.2K
Annual income after 10y$183,899.77$607,376.13
Total dividends collected$633.8K$926.2K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: CBLI vs VICI ($10,000, DRIP)

YearCBLI PortfolioCBLI Income/yrVICI PortfolioVICI Income/yrGap
1$17,009$6,309.15$11,361$941.49+$5.6KCBLI
2$28,229$10,029.27$13,320$1,481.32+$14.9KCBLI
3$45,761$15,556.06$16,284$2,405.01+$29.5KCBLI
4$72,532$23,567.66$21,040$4,071.78+$51.5KCBLI
5$112,521$34,911.29$29,209$7,285.49+$83.3KCBLI
6$171,013$50,615.56$44,443$14,006.51+$126.6KCBLI
7$254,878$71,894.60$75,822$29,512.55+$179.1KCBLI
8$372,862$100,142.13$148,733$69,726.75+$224.1KCBLI
9$535,876$136,914.14$344,394$189,413.75+$191.5KCBLI
10← crossover$757,287$183,899.77$966,234$607,376.13$208.9KVICI

CBLI vs VICI: Complete Analysis 2026

CBLIStock

Cleveland BioLabs, Inc. operates as a biopharmaceutical company, which engages in the research and development of drugs. The company is headquartered in Buffalo, New York and currently employs 15 full-time employees. The firm is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.

Full CBLI Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this CBLI vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CBLI vs SCHDCBLI vs JEPICBLI vs OCBLI vs KOCBLI vs MAINCBLI vs NNNCBLI vs EPRTCBLI vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.